Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment

Dow Jones2025-12-18

By Elias Schisgall

Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.

The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.

Cardamyst received Food and Drug Administration approval last week.

Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.

"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery," Aptar Pharma President Gael Touya said. "We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area."

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

December 17, 2025 17:26 ET (22:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592946247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592946247","market":"us","top_or_hot":-1,"title":"Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-18 06:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ATR\">Aptar</a> Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n</p>\n<p>\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n</p>\n<p>\n  Cardamyst received Food and Drug Administration approval last week. \n</p>\n<p>\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n</p>\n<p>\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 17:26 ET (22:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATR","symbol_name":"Aptar","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592946247","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592946247","pubTimestamp":1766010360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.Cardamyst received Food and Drug Administration approval last week.Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.\"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now avai","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATR":"Aptar","BK4126":"金属与玻璃容器"},"translate_title":"Aptar的鼻内技术将用于Milestone获得FDA批准的心脏治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nAptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults. \n\n\n  The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate. \n\n\n  Cardamyst received Food and Drug Administration approval last week. \n\n\n  Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors. \n\n\n  \"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now available for patients in yet another therapeutic area.\" \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 17:26 ET (22:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592946247","isCrawlerRequest":true}